Naviswiss, a Swiss-based medical device company, receives FDA approval to market Naviplan in the United States. Naviplan is a digital preoperative planning application that allows orthopedic surgeons to perform a navigated CT -based total hip arthroplasty. This has the potential to improve accuracy and predictability and provide complete documentation of the outcome.
Naviswiss, the technology leader in miniaturized surgical navigation solutions, assists orthopedic surgeons in the precise positioning of hip replacement implants. The Naviplan hip application is based on CT and supports the surgeon in the optimal positioning of joint implants, automatic 3D segmentation, and advanced image processing. Naviplan passes the preoperative plan to the Naviswiss navigation platform for precise surgical execution.
“Naviplan and CT-based Navigation are an important addition to the Naviswiss portfolio and complete our offering for navigated hip replacement,” commented Jan Stifter, Naviswiss CEO. “We now have two patient-specific options where the surgeon determines the best application for the procedure. CT-based Navigation may be needed in difficult deformity cases while kinematic registration may be preferred in more traditional surgeries. The surgeon can rely on highly accurate guidance in placing the acetabular components.”
Naviswiss is releasing the CT-based Navigation and Naviplan to orthopedic care centers in the United States over the fourth quarter of 2021.
